Effective anti-tuberculosis therapy correlates with plasma small RNA

To the Editor:

Small RNA (smRNA) is a diverse family of translation regulation molecules, which includes microRNA (miRNA). Changes in miRNA have been reported in association with respiratory disease [1] and in mycobacterial infection [2]. Studies have measured concentrations of miRNA pooled from multiple subjects with active tuberculosis (TB) disease compared with latently infected individuals and healthy controls [3]. However, this approach cannot assess variation between individuals, nor does it describe changes that might occur with treatment, both of which may be helpful in characterising and predicting patient outcome.

Here, we investigated plasma host smRNA in adults being treated for pulmonary TB. 41 subjects with confirmed smear-positive pulmonary TB were recruited prospectively in Durban, South Africa. Three were excluded due to missing time-points during follow-up. 29 (76.3%) out of 38 subjects were male and 19 (50%) out of 38 were HIV-1 co-infected. Treatment was with a standard drug regimen for pulmonary TB: 2 months of isoniazid (INH), rifampicin (RIF), ethambutol and pyrazinamide, followed by 4 months of INH and RIF. At day 0 (pretreatment) and week 24 (treatment completion) each patient had 50 mL whole blood collected into K3-EDTA vacutainers (BD, Gauteng, South Africa) by venepuncture. Plasma was frozen at −80°C until required. This study was approved by the Biomedical Research Ethics Committee of the University of Kwa-Zulu Natal (approval number: BF 138/09); and conducted in compliance with ICH Good Clinical Practice Guidelines. All patients provided informed consent.

Haemolysis has been found to affect plasma miRNA concentration if absorbance at 414 nm (A414) is >0.2 at [4, 5]. We measured haemoglobin (Hb) according to HARBOE [6] and excluded paired samples with Hb differences >0.5 g·L−1 (equivalent to an absorbance of 0.2 at A414 in our system), which made up four (10.5%) out of the 38 subjects.

smRNA was extracted from 200 μL plasma before and after anti-TB treatment (n=34; 17 with HIV-1 co-infection) using the miRNeasy mini kit (Qiagen, Germantown, MD, USA), according to the manufacturer’s instructions. 30 individuals were culture-negative at week 24, 14 of whom were HIV-1 co-infected (all patients produced sputum at week 24 and this was tested). Four individuals had sputum that was still culture-positive at week 24, three of whom were HIV-1 co-infected. Of these, one had drug-sensitive TB, one had INH resistance and two had multidrug-resistant (MDR)-TB.

Plasma smRNA concentration (6–150 nucleotides) was determined using the 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). Those who culture-converted had significantly higher plasma smRNA (6–150 nucleotides) pretreatment (day 0) compared with post-treatment (week 24) (day 0 median (interquartile range (IQR)) 353 (238–573) pg·μL−1, week 24 median (IQR) 83 (53–146) pg·μL−1; p<0.0001) (fig. 1a). Individuals who failed therapy (n=4) did not have a similar decline in smRNA (day 0 median (IQR) 115 (86–515) pg·μL−1, week 24 median (IQR) 348 (165–554) pg·μL−1; p>0.05) (fig. 1b). Absolute measures of smRNA in plasma were variable between patients, precluding use of absolute concentrations to inform disease status. Despite small numbers there was a significant difference in plasma smRNA concentration before and after treatment for those who culture-converted compared with treatment failures (≥10% increase or decline in smRNA concentration between the two time-points was considered a change; p=0.02 using Fisher’s exact test).

Host nucleic acid in serum was first noted in 1978 [7], but its function and source remain unknown. We found no correlation between blood CD4+ T-cell count and concentration of smRNA at day 0 for HIV-positive subjects (Spearman rank correlation r=0.25, p=nonsignificant; data not shown), suggesting CD4+ T-cells are not the primary source of plasma smRNA. This does not rule out production from other blood cells or disease site.

Co-infection with HIV-1 did not affect decline in plasma smRNA after anti-TB treatment (both p<0.001) (fig. 1c, d); and there was no significant difference in smRNA between HIV-1 infected or uninfected subjects at day 0 or week 24 (both p>0.05) (fig. 1c, d).
Small RNA (smRNA) profiles in plasma of tuberculosis (TB) infected individuals before and after treatment. a–d) Wilcoxon paired analysis of plasma smRNA concentration (6–150 nucleotides) before (day 0) and after (week 24) anti-TB treatment for individuals with active TB. a) Individuals who were culture negative at week 24 (n=30) and b) who were culture positive at week 24 (n=4). smRNA according to HIV status: c) HIV-negative individuals; and d) HIV co-infected individuals. NS: nonsignificant. e, f) Fold change for four individual smRNA genes at day 0 (pretreatment) compared with week 24 (after treatment) in those that culture converted by week 24 (circles, n=30) compared with those who were culture-positive at week 24 (triangles, n=4). p-values are uncorrected. #: indicates statistical significance after Bonferroni correction. Grey symbols: HIV-negative; black symbols: co-infected with HIV-1, antiretroviral therapy naïve; white symbols: co-infected with HIV-1, receiving antiretroviral therapy. g) Cluster diagram using the four individually tested microRNA species (miR-29a, 17-3p, 133a, and SNORD61). (+): indicates those who were culture-positive after treatment completion.
Plasma small RNA concentration declines in response to anti-tuberculosis therapy and is independent of HIV-status

Isobella Honeyborne¹, Marc C. Lipman³, Clare Eckold¹, Dimitrios Evangelopoulos⁵, Stephen H. Gillespie⁵, Alexander Pym⁴ and Timothy D. McHugh¹

¹Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK. ²Centre for Respiratory Medicine, University College London, London, UK. ³School of Medicine, Medical and Biological Sciences, University of St Andrews, St Andrews, UK. ⁴K-RITH (KwaZulu-Natal Research Institute for Tuberculosis and HIV), Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.

Rotorgene-100 human serum/plasma MIHS-106Z arrays (SA Biosciences, Germantown, MD, USA) were used to measure 84 miRNAs and five small nucleolar RNAs (snoRNAs). Day 0 and week 24 miRNA was converted to cDNA for eight individuals (five HIV-negative individuals and three HIV-1 co-infected) and tested on individual arrays. Mean fold changes for each smRNA were determined using the previously described ΔΔCt method [8, 9]. No detection for a smRNA was assigned a cycle threshold of 40. Cycles <40 were included and considered positive.

20 out of 90 tested smRNAs were raised at day 0 compared with week24 and none decreased (≥2-fold, p<0.05; data not shown). After correction all statistical significance was lost indicating measurement of any individual smRNA was no more discriminatory than total smRNA concentration. In a previous study, pooled serum from Mycobacterium tuberculosis-infected individuals, compared with healthy controls, had 59 out of 1223 miRNAs increased and 33 decreased in the active TB group [3]. A study of paediatric TB observed miR-21 and miR-26a increased in peripheral blood in response to treatment [10]. That we found no miRNA molecules increased in response to therapy may reflect our measurement of miRNA in plasma rather than in CD4⁺ T-cells [10]. A study comparing peripheral blood and pleural fluid in TB-infected individuals suggested a differential compartmentalisation of miRNA at the disease site compared with peripheral blood [11].

Despite a previous reported association between active TB and increased miR-29a in serum [3], and a potential mechanism due to interaction with the interferon-γ gene [12], we found, similar to miR-133a and SNORD61, only a trend towards a difference in fold change for miR-29a in those who culture-converted (n=30) compared with those who did not (n=40) (fig. 1c, f). Change in miR-17-3p was weakly statistically significant after correction (p=0.04). There was a large inter-patient range in smRNA fold change between individuals for all smRNAs tested. It is possible this could reflect differences such as sterilising cure versus return to latency, high variability in the immune response or the severity of disease at clinic presentation.

HIV status did not appear to affect our observations, whereas a previous report found some miRNAs associated with high HIV-1 viral load in individuals without active TB [13]. Most HIV-1 co-infected subjects in our study were antiretroviral therapy (ART) naïve, suggesting viral suppression is not a prerequisite for decline in smRNA at TB treatment completion. Although only five (29%) out of 17 HIV-1 co-infected individuals were using ART, there appeared to be no significant impact on detection of SNORD61, miR-17-3p or miR-133a compared with either HIV-negative or HIV-positive but ARV naïve subjects. For miR-29a, those who were both on ART and culture-negative at week 24 all had fold changes above the median.

snoRNAs have been characterised as a structural scaffold for ribosome assembly [14]. SnoRNAs have not been previously investigated in M. tuberculosis infection and snoRNA would not be expected to be present outside of the nucleolus. However, several snoRNA molecules have been observed to accumulate in the cytosol in times of cellular stress [15], which may suggest additional functions for these molecules.

We performed cluster analysis to test whether using multiple smRNA expression ratios (miR-17-3p, SNORD61, miR-29a and miR-133a) would increase the utility of smRNA for determining culture status at week 24. Three of the subjects (D32, D33 and D34) who were still culture-positive at week 24 all had fold changes above the median. Despite a previous reported association between active TB and increased miR-29a in serum [3], and a potential mechanism due to interaction with the interferon-γ gene [12], we found, similar to miR-133a and SNORD61, only a trend towards a difference in fold change for miR-29a in those who culture-converted (n=30) compared with those who did not (n=40) (fig. 1c, f). Change in miR-17-3p was weakly statistically significant after correction (p=0.04). There was a large inter-patient range in smRNA fold change between individuals for all smRNAs tested. It is possible this could reflect differences such as sterilising cure versus return to latency, high variability in the immune response or the severity of disease at clinic presentation.

In summary, we find changes in plasma smRNA concentration are predictive of individuals who have responded to anti-TB treatment at week 24, independent of HIV-1 co-infection, and that measurement of total smRNA or a combination of smRNA markers present in plasma may be a useful marker of treatment response in active TB. Such markers could potentially be utilised to provide a rapid indication of therapy success or failure in the clinic.

@ERSpublishations

Plasma small RNA concentration declines in response to anti-tuberculosis therapy and is independent of HIV-status http://ow.ly/IXoAD
Correspondence: Isobella Honeyborne, Centre for Clinical Microbiology, Dept of Infection, University College London, Royal Free Campus, Rowland Hill Street, London, NW3 2PF, UK. E-mail: l.honeyborne@ucl.ac.uk

Received: Sept 21 2014 | Accepted after revision: Jan 15 2015

Support statement: This work was supported in part by the Medical Research Council (grant number: G0601466). M.C. Lipman is a Higher Education Funding Council for England Clinical Senior Lecturer. Funding information for this article has been deposited with FundRef

Conflict of interest: Disclosures can be found alongside the online version of this article at erj.ersjournals.com

Acknowledgements: We would like to thank S. Bokhari and S. Christou (Centre for Clinical Microbiology, Dept of Infection, University College London, London, UK) for assistance with sample processing and C. Smith (Research Dept of Infection and Population Health, University College London, London, UK) for statistical support.

References

10 Kleinsteuber K, Heesch K, Schattling S, et al. Decreased expression of miR-21, miR-26a, miR-29a, and miR-142-3p in CD4+ T cells and peripheral blood from tuberculosis patients. PLoS One 2013; 8: e61609.